Pink Sheet Podcast: CMS Listens On Price Negotiations, Elevidys Top-Line Trial Data, Gene Therapy Reg Changes

Pink Sheet reporters and editor discuss take-aways from the first Medicare price negotiation program public listening sessions, next steps after Sarepta reported questionable top-line data for its Duchenne muscular dystrophy gene therapy Elevidys, and indications the FDA may adjust its regulatory approach to gene editing products.